- Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Bausch + Lomb (NYSE:BLCO) securities
- On March 27th, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome (TASS), a potential complication in cataract surgery
- Following the announcement, Bausch + Lomb’s stock price dropped US$1.50 per share, or 10.6 per cent, closing at US$15.00 on the same day
- Bausch + Lomb stock (NYSE:BLCO) opened trading at US$13.94
Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Bausch + Lomb (NYSE:BLCO) securities. Investors who acquired Bausch + Lomb shares are encouraged to obtain additional information and assist in the ongoing investigation.
On March 27th, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome (TASS), a potential complication in cataract surgery. TASS is an inflammatory reaction within the eye that can occur after cataract surgery, leading to concerns about product safety and regulatory scrutiny.
Following the announcement, Bausch + Lomb’s stock price dropped US$1.50 per share, or 10.6 per cent, closing at US$15.00 on the same day. The recall has raised short-term concerns among investors regarding the safety of the company’s products and potential regulatory implications.
Bronstein, Gewirtz & Grossman, LLC is urging investors who purchased Bausch + Lomb securities to come forward with any relevant information that may assist in the investigation. The firm aims to protect the rights of shareholders and ensure that any potential misconduct is thoroughly examined.
Other firms, such as Levi & Korsinsky and Rosen Law are also investigating the company on this issue.
Bausch + Lomb Corp. is an eye health company. It operates through three segments: Vision care, pharmaceuticals, and surgical.
Bausch + Lomb stock (NYSE:BLCO) opened trading at US$13.94.
Join the discussion: Find out what everybody’s saying about this stock on the Bausch + Lomb Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
